50
Participants
Start Date
September 29, 2017
Primary Completion Date
March 17, 2021
Study Completion Date
April 7, 2021
BI 409306
50 milligrams BI 409306, as a film-coated tablet, orally twice a day at approximately the same time every day in the morning and in the evening (approximately 12 hours apart) with or without food for 52 weeks.
Placebo
placebo matching 50 milligrams BI 409306, as a film-coated tablet, orally twice a day at approximately the same time every day in the morning and in the evening (approximately 12 hours apart) with or without food for 52 weeks.
New York State Psychiatric Institute, New York
Finger Lakes Clinical Research, Rochester
University of Pennsylvania, Philadelphia
The University of North Carolina at Chapel Hill, Chapel Hill
Augusta University, Augusta
University of Florida College of Medicine, Jacksonville
Medical Research Group of Central Florida, Orange City
Vanderbilt University Medical Center, Nashville
Precise Research Centers, Flowood
University of Cincinnati, Cincinnati
Michigan Clinical Research Institute PC, Ann Arbor
University of Michigan Health System, Ann Arbor
Cherry Health, Grand Rapids
University Hills Clinical Research, Irving
Community Clinical Research, Inc., Austin
Psychiatric and Behavioral Solutions, LLC, Salt Lake City
Altea Research Institute, Las Vegas
ProScience Research Group, Culver City
University of California San Diego, San Diego
PeaceHealth Medical Group, Eugene
Peking University Sixth Hospital, Beijing
Shanghai Mental Health Center, Shanghai
PRIME Clinic, New Haven
Boston Medical Center, Boston
Center For Emotional Fitness, Cherry Hill
University of Calgary, Calgary
University of Alberta Hospital (University of Alberta), Edmonton
Chatham-Kent Clinical Trials Research Centre, Chatham
Alan D. Lowe Medicine Professional Corporation, Toronto
Holywell Hospital, Antrim
The Barberry National Centre for Mental Health, Birmingham
King's College Hospital, London
University of Manchester, Manchester
Lead Sponsor
Boehringer Ingelheim
INDUSTRY